Amir Shojaei Biography and Net Worth

Insider of Harrow

Amir H. Shojaei was named Harrow’s Chief Scientific Officer in January 2025, bringing with him nearly 30 years of experience in the life sciences sector. A recognized leader in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, Dr. Shojaei oversees Harrow’s medical and clinical affairs, regulatory affairs, pharmacovigilance and QA/compliance for FDA-approved products. Throughout his career, Dr. Shojaei has been instrumental in the advancement of innovative treatments for anterior and posterior segment eye diseases. Notable, he led the development and FDA approval of Xiidra®, a groundbreaking therapy and the first product to treat both the signs and symptoms of dry eye disease. Prior to joining Harrow, he held senior leadership roles at several prominent biopharmaceutical companies, including AsclepiX Therapeutics, TherOptix, Novartis Pharmaceuticals, and Shire Pharmaceuticals (acquired by Takeda). Dr. Shojaei holds a Pharm.D. and Ph.D. from the University of the Pacific. In addition, he is the holder of multiple patents and has authored over 25 peer-reviewed publications.

What is Amir Shojaei's net worth?: The estimated net worth of Amir Shojaei is at least $469.24 thousand as of August 14th, 2026. Shojaei owns 11,250 shares of Harrow stock worth more than $469,238 as of August 20th. This net worth approximation does not reflect any other investments that Shojaei may own. Learn More about Amir Shojaei's net worth.
How do I contact Amir Shojaei?: The corporate mailing address for Shojaei and other Harrow executives is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. Harrow can also be reached via phone at (615) 733-4730 and via email at [email protected]. Learn More on Amir Shojaei's contact information.
Has Amir Shojaei been buying or selling shares of Harrow?: Within the last three months, Amir Shojaei has sold $450,000.00 in shares of Harrow stock. Most recently, Amir Shojaei sold 11,250 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.00, for a transaction totalling $450,000.00. Following the completion of the sale, the insider now directly owns 11,250 shares of the company's stock, valued at $450,000. Learn More on Amir Shojaei's trading history.
Who are Harrow's active insiders?: Harrow's insider roster includes Mark Baum (Chief Executive Officer and Chairman of the Board of Directors), Andrew Boll (President & Chief Financial Officer), Adrienne Graves (Director), Richard Lindstrom, MD (Director), and Amir Shojaei (Insider). Learn More on Harrow's active insiders.
Are insiders buying or selling shares of Harrow?: In the last twelve months, Harrow insiders bought shares 2 times. They purchased a total of 4,500 shares worth more than $135,720.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,250 shares worth more than $450,000.00. The most recent insider tranaction occured on August, 14th when insider Amir Shojaei sold 11,250 shares worth more than $450,000.00. Insiders at Harrow own 12.8% of the company. Learn More about insider trades at Harrow.
Information on this page was last updated on 8/14/2026.

Amir Shojaei Insider Trading History at Harrow

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2026	Sell	11,250	$40.00	$450,000.00	11,250

Amir Shojaei Buying and Selling Activity at Harrow

Harrow Company Overview

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $42.06

$41.24

$42.71

50 Day Range

MA: $41.31

$37.46

$46.65

2 Week Range

Now: $42.06

$28.54

$54.85

Volume

450,036 shs

Average Volume

728,655 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28